Black Friday saleUp to 70% OFF
GGG

GENTIAN DIAGNOSTICS ASA

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Forecast Seasonals

GENT chart


Full chart

GENT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪638.49 M‬ NOK
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
285.2
Basic EPS (TTM)
0.2 NOK
Net income (FY)
‪−10.65 M‬ NOK
Revenue (FY)
‪135.15 M‬ NOK
Shares float
‪7.50 M‬
Beta (1Y)
0.11

Employees


Employees (FY)
58
Change (1Y)
+3 +5.45%
Revenue / Employee (1Y)
‪228.77 K‬ NOK
Net income / Employee (1Y)
‪−18.02 K‬ NOK

About GENTIAN DIAGNOSTICS ASA


Sector
Health Technology
Industry
Medical Specialties
CEO
Njaal Kind
Website
gentian.no
Headquarters
Moss
Founded
2001
ISIN
NO0010748866
FIGI
BBG00FJC6841
Gentian Diagnostics ASA engages in the research, development, production, marketing, and distribution of immunoassays. Its products include GCAL Calprotrectin, Crystatin C, Retinol-Binding Protein, Canine CRP, SARS-CoV-2 Total Ab, NT-proBNP Pre-Launch, BÜHLMANN products, IFU documents, and safety data sheets. The company was founded by Erling M. H. Sundrehagen and Bård Sundrehagen in 2001 and is headquartered in Moss, Norway.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

GENT news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of GENT is 39.4 NOK — it has decreased by −2.90% in the past 24 hours. Watch GENTIAN DIAGNOSTICS ASA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OSL exchange GENTIAN DIAGNOSTICS ASA stocks are traded under the ticker GENT.
GENT stock has fallen by −2.43% compared to the previous week, the month change is a −6.07% fall, over the last year GENTIAN DIAGNOSTICS ASA has showed a −1.01% decrease.
We've gathered analysts' opinions on GENTIAN DIAGNOSTICS ASA future price: according to them, GENT price has a max estimate of 67.00 NOK and a min estimate of 67.00 NOK. Watch GENT chart and read a more detailed GENTIAN DIAGNOSTICS ASA stock forecast: see what analysts think of GENTIAN DIAGNOSTICS ASA and suggest that you do with its stocks.
GENT reached its all-time high on Aug 27, 2020 with the price of 89.0 NOK, and its all-time low was 22.0 NOK and was reached on Dec 14, 2016. View more price dynamics on GENT chart.
See other stocks reaching their highest and lowest prices.
GENT stock is 5.58% volatile and has beta coefficient of 0.11. Track GENTIAN DIAGNOSTICS ASA stock price on the chart and check out the list of the most volatile stocks — is GENTIAN DIAGNOSTICS ASA there?
Today GENTIAN DIAGNOSTICS ASA has the market capitalization of ‪638.49 M‬, it has decreased by −2.84% over the last week.
Yes, you can track GENTIAN DIAGNOSTICS ASA financials in yearly and quarterly reports right on TradingView.
GENTIAN DIAGNOSTICS ASA is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
GENT net income for the last quarter is ‪3.41 M‬ NOK, while the quarter before that showed ‪4.73 M‬ NOK of net income which accounts for −27.87% change. Track more GENTIAN DIAGNOSTICS ASA financial stats to get the full picture.
No, GENT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 58.00 employees. See our rating of the largest employees — is GENTIAN DIAGNOSTICS ASA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENTIAN DIAGNOSTICS ASA EBITDA is ‪12.46 M‬ NOK, and current EBITDA margin is −5.18%. See more stats in GENTIAN DIAGNOSTICS ASA financial statements.
Like other stocks, GENT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENTIAN DIAGNOSTICS ASA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENTIAN DIAGNOSTICS ASA technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENTIAN DIAGNOSTICS ASA stock shows the sell signal. See more of GENTIAN DIAGNOSTICS ASA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.